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A B S T R A C T
HTLV type 1 and 2 are both involved in actively spreading epidemics, affecting over 15 million people
worldwide. HTLV-1 has been described as the more clinically signiﬁcant one, being associated with
diseases such as adult T-cell leukemia and tropical spastic paraparesis. We report here a case of tropical
spastic paraparesis in an HIV-positive patient who did not report any history of travel or residence in an
HTLV endemic area.
A 57 year old African-American male was admitted to the hospital due to bilateral upper and lower
extremity weakness associated with stiffness. He had recently been diagnosed with HIV. His physical
examination showed mild to moderate decreased motor strength, in both upper extremities and marked
loss in both lower extremities. This was associated with hyperreﬂexia and clonus. Sensory function was
intact. He looked cachectic and had several psoriatic plaques on both lower and upper extremities.
Laboratory work-up showed a CD4 count decreased to 94 cells/mm3 and a HIV viral load of
273,000 copies/mL. Based on serum positivity for HTLV type 1 and the patient’s clinical presentation
suggestive of upper and lower motor neuron dysfunction, the diagnosis of tropical spastic paraparesis
was made.
HTLV and HIV share the same routes of transmission and the same tropism for T-lymphocytes. Co-
infection occurs probably more frequently than we are aware, since testing for HTLV is not routinely
performed in outpatient HIV clinics.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Human T-cell lymphotropic virus (HTLV) was initially identiﬁed
in 1979 and it represents the ﬁrst human retrovirus ever described
[1]. It belongs to the Retroviridae family, in the genus Deltare-
trovirus, and predominantly affects T lymphocytes. Its genome is a
positive single-stranded RNA [2]. So far, 4 types of HTLV have been
established, but speciﬁc illnesses have been associated only with
type 1 and 2. HTLV type 1 and 2 are both involved in actively
spreading epidemics, affecting over 15 million people worldwide
[3]. HTLV-1 has been described as the more clinically signiﬁcant
one, being associated with diseases such as adult T-cell leukemia
and tropical spastic paraparesis. HTLV and HIV share the same
routes of transmission and the same tropism for T-lymphocytes.
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4.0/).since testing for HTLV is not routinely performed in outpatient HIV
clinics [4]. We report here a case of tropical spastic paraparesis in
an HIV-positive patient who did not report any history of travel or
residence in an HTLV endemic area.
Case report
A 57 year old African-American male was admitted to the
hospital due to bilateral upper and lower extremity weakness
associated with stiffness, more severe in his lower extremities. His
symptoms had started several months prior to this presentation
and had gradually worsened to the point that he was no longer able
to ambulate. He denied any fever, chills, seizures or any history of
trauma.
His past medical history was signiﬁcant for psoriasis and HIV,
diagnosed eight months prior. He was not enrolled in HIV care and
he was not on any medications at home. He had no past surgical
history. The patient denied tobacco use, alcohol abuse or any illicit
drug use. He was born in Florida, United States, and had nevere under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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with female partners only and his last sexual contact was about
one year prior. Review of systems was positive for bilateral upper
and lower extremity weakness and stiffness, with generalized pain
upon movement, and increased urinary frequency. His physical
examination was remarkable for mild to moderate decreased
motor strength, in both upper extremities and marked loss in both
lower extremities. This was associated with hyperreﬂexia and
clonus. Sensory function was intact. He looked cachectic and had
several psoriatic plaques on both lower and upper extremities.
Magnetic resonance imaging of the brain, with and without
intravenous contrast, showed only non-speciﬁc bilateral symmet-
ric white matter changes. Magnetic resonance imaging of the
cervical, thoracic and lumbosacral spine, with and without
intravenous contrast, was interpreted as normal.
Laboratory work-up showed a CD4 count decreased to 94 cells/
mm3 and HIV viral load by PCR of 273,000 copies/mL. His white
blood count was 4  103/mm3 and hemoglobin was 11.6 g/dL.
Platelets were within normal limits at a level of 186  103/mm3.
Renal, hepatic and thyroid function, as well as electrolytes, were all
within normal limits. Cerebrospinal ﬂuid analysis showed 102 red
blood cells/mm3, 42 white blood cells/mm3 with 100% lympho-
cytes, normal protein, normal glucose and negative bacterial,
fungal and mycobacterial cultures. VDRL, CMV PCR, JC PCR, HSV
PCR, Cryptococcal antigen and West Nile virus IgM and IgG were all
negative in the cerebrospinal ﬂuid. HTLV-1 antibodies were
negative in CSF, but positive in serum by enzyme-linked
immunosorbent assay and conﬁrmed by Western blot.
Based on serum positivity for HTLV type 1 and the patient’s
clinical presentation suggestive of upper and lower motor neuron
dysfunction, the diagnosis of tropical spastic paraparesis was
made. He was started on symptomatic treatment with muscle
relaxants and gabapentin. He was also started on HIV treatment
with tenofovir/emtricitabine, atazanavir and ritonavir. He was also
started on opportunistic infection prophylaxis with daily trimeth-
oprim-sulfamethoxazole and weekly azithromycin. He was dis-
charged to a physical rehabilitation center. One year after initial
presentation he had gained over 50 lbs and his lower extremity
weakness and stiffness had improved. He was able to walk with a
rolling walker. His CD4 count had increased to 169 cells/mm3 and
HIV viral load had decreased to less than 20 copies/mL.
Discussion
Human T-cell virus type 1 (HTLV-1) is well recognized as the
cause of tropical spastic paraparesis (TSP), disease that is also
known as HTLV-1-associated myelopathy (HAM) [5]. TSP/HAM is
an upper motor neuron syndrome that primarily affects the lower
extremities. It presents as a slowly progressive spastic paraparesis
and the sensory signs are generally less evident. This syndrome can
develop as early as three months after infection with HTLV-1 [6],
but an average of three years of latency is more typical, and 20–30
years is possible [2]. An age of onset at 50 years or older is usually
associated with a more rapid progression to a severe disability.
The diagnosis of TSP/HAM is based mainly on history and
physical exam, in context of positive HTLV-1 serology. HTLV
infections are detected with enzyme-linked immunosorbent assay
(ELISA), which then must be conﬁrmed with Western blot,
immunoﬂuorescence assay (IFA), or polymerase chain reaction
(PCR). Spine imaging studies are done mostly to rule out other
causes of myelopathy. Magnetic resonance imaging of spine may
show evidence of demyelination in patients with TSP/HAM and
similar changes can be seen also in the periventricular white
matter. However, these lesions also occur in patients with
asymptomatic HTLV-1 infections, and comparisons with controlshave not been adequate [7]. The mainstay of treatment for TSP/
HAM is symptomatic. No standard treatment is currently available.
The interaction of HIV and HTLV remains poorly understood,
and there is clearly need for further research into the epidemiolo-
gy, pathogenesis and treatment of this co-infection. Both HTLV-1
and HTLV-2 appear to have an effect on the clinical progression of
HIV disease, and HIV infection has an inﬂuence on the clinical
manifestations of HTLV.
It is estimated that rates of HTLV-1 or 2 co-infection in HIV
infected individuals are at least 100–500 times greater than in
general population. There are some geographic areas where up
to 20% of HIV infected individuals may be co-infected with
HTLV-1 [8].
HTLV-1 and HIV-1 co-infection
HTLV-1 predominantly affects CD4 lymphocytes. In vitro,
HTLV-1 is also capable of infecting other cell types and this has
been attributed to the fact that one of its host-receptors is GLUT-1,
an ubiquitous glucose transporter.
HTLV-1/HIV-1 co-infection is more frequently reported in South
America, the Caribbean and Africa [8–10]. Studies suggest that
HTLV-1/HIV-1 co-infection is associated with a modiﬁcation of the
natural history of HIV-1, with a faster clinical progression to AIDS
and a shorter survival time [11]. HIV-1 appears to up-regulate
HTLV-1 expression, leading to a higher risk of HTLV-1 associated
diseases, such as TSP/HAM and adult T-cell leukemia. However,
clinical evidence remains controversial due to methodological
problems in the majority of currently published studies [12].
An early study of HIV and HTLV-1 co-infection done by Leung
et al. in 1988 [13] reported that co-infection with HTLV-1 led to
increased production of speciﬁc host cell proteins which results in
stimulation of HIV replication. In 1994 Schechter et al. published a
case-control study of 27 patients with HIV/HTLV-1 co-infection
[14] and concluded that co-infection was associated with higher
CD4 counts, but at the same time with evidence of more advanced
HIV clinical disease. A case–control, retrospective study, published
in 2001 by Brites et al. [8] of 198 HIV-1 infected patients, of which
63 cases were co-infected with HTLV-1 concluded that HIV-1/
HTLV-1 co-infected patients had a shorter mean survival than the
HIV-1 mono-infected patients, regardless of sex or baseline CD4
cell count. Sobesky et al. found an increased risk of death for HIV-1/
HTLV-1 co-infected patients from French Guiana, compared to
HIV-1 mono-infected ones, but the power of their conclusion was
limited by small sample size. Out of 151 HIV-infected patients that
were included in this study, only 18 patients were co-infected [15].
In 2004 Beilke et al. published a longitudinal study, done in New
Orleans, that looked at 62 patients with HIV/HTLV-1 co-infection
and compared them to a group of 824 HIV-mono-infected patients.
They found no signiﬁcant differences in progression to AIDS,
presence of opportunistic infections or death between these two
groups [16]. There were though some methodological issues that
may have inﬂuenced their results. This study included patients
that were on antiretroviral medications, while some of the prior
studies were done in the pre-HAART era. Beilke et al. mention that
they adjusted the analysis for the use of antiretroviral drugs, but
there is no description in the article on the duration of HAART
therapy, patient follow-up or time when antiretroviral medication
was started in HIV mono-infected patients, as compared to co-
infected ones [17].
HTLV-2 and HIV-1 co-infection
HIV-1/HTLV-2 co-infection predominates in North America and
Europe, especially among IV drug users [18]. The available
evidence suggests a possible protective role of HTLV-2 co-infection
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infected patients had lower levels of T-cell activation with lower
rate of HIV replication [18]. In the retrospective study published
by Beilke et al., 141 patients with HIV/HTLV-2 co-infection were
compared to 824 patients who were HIV-mono-infected. Their
conclusion was that HIV/HTLV-2 co-infection was statistically
associated with delayed progression to both AIDS and death [16].
A longitudinal study by Turci and al. of 2371 HIV-1 infected
Caucasian, intravenous drug users from Italy, of whom 6.7% were
co-infected with HTLV-2, found that the co-infected patients were
older aged, had higher baseline CD4 counts and delayed
progression to AIDS [20].
Conclusions
HIV and HTLV-1/2 co-infection may occur more frequent than
we are aware of, since routine testing for HTLV-1/2 in outpatient
HIV clinics is not currently recommended. HTLV-1 and HTLV-2 co-
infection seem to have different effects on HIV infected individuals.
It appears that HTLV-1 may accelerate clinical progression to AIDS
and the HIV virus may promote a higher risk of HTLV-1 associated
diseases. However, some of the available data is contradictory.
HTLV-2 co-infection seems to have a protective role, decreasing
progression to AIDS. One common denominator between HTLV-1
and HTLV-2 co-infection in HIV patients, is that both have been
linked to higher CD4 counts. The higher CD4 counts may have
resulted in a delay in introduction of antiretroviral therapy in these
co-infected patients [12].
There is deﬁnitely a need for larger, well designed studies in
order to clearly determine the impact of HIV/HTLV-1/2 co-
infection.
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